{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:11Z","timestamp":1791828851208,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1136\/ard.2009.112136","type":"journal-article","created":{"date-parts":[[2010,5,7]],"date-time":"2010-05-07T02:53:55Z","timestamp":1273200835000},"page":"1612-1617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"69","author":[{"given":"Jeremy","family":"Sokolove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Anofrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2009.112136_bib1","first-page":"459","article-title":"Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis","volume":"23","author":"Kremer","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2009.112136_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.1780360307","article-title":"Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis","volume":"36","author":"Walker","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.112136_bib3","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.2009.112136_bib4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/art.11452","article-title":"Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients","volume":"49","author":"Siva","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.112136_bib5","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/art.11015","article-title":"The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study","volume":"48","author":"Kalden","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.112136_bib6","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/1529-0131(200108)44:8<1966::AID-ART339>3.0.CO;2-3","article-title":"Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles","volume":"44","author":"Saleem","year":"2001","journal-title":"etal Arthritis Rheum"},{"key":"10.1136\/ard.2009.112136_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200427050-00006","article-title":"Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity","volume":"27","author":"van Roon","year":"2004","journal-title":"Drug Saf"},{"key":"10.1136\/ard.2009.112136_bib8","unstructured":"Remicade,. Summary of Product Characteristics (SPC). Centocor, Malvern, Pennsylvania, USA, April 2007."},{"key":"10.1136\/ard.2009.112136_bib9","first-page":"199","article-title":"No increase in hepatic side effects or hospitalizations among RA patients using biologic treatment for rheumatoid arthritis","volume":"63","author":"Wolfe","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.112136_bib10","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.mib.0000246783.75753.9f","article-title":"Infliximab single administration followed by acute liver injury","volume":"12","author":"Ierardi","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/ard.2009.112136_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4065\/76.1.84","article-title":"Infliximab-associated reversible cholestatic liver disease","volume":"76","author":"Menghini","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1136\/ard.2009.112136_bib12","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/ibd.20230","article-title":"Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab","volume":"13","author":"Moum","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/ard.2009.112136_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","article-title":"Serious liver disease induced by infliximab","volume":"26","author":"Tobon","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2009.112136_bib14","first-page":"349","article-title":"Granulomatous hepatitis associated with etanercept therapy","volume":"35","author":"Farah","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2009.112136_bib15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jbspin.2007.12.009","article-title":"Infliximab-induced hepatitis: absence of cross-toxicity with etanercept","volume":"75","author":"Thi\u00e9fin","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard.2009.112136_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.112136_bib17","first-page":"561","article-title":"Hepatotoxicity of salicylazosulfapyridine: a case report and review of the literature","volume":"72","author":"Gulley","year":"1979","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/ard.2009.112136_bib18","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/art.1780380904","article-title":"Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables","volume":"38","author":"Kremer","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.112136_bib19","unstructured":"Enbrel package insert. Amgen Corp, Thousand Oaks, California, USA, December 2006."},{"key":"10.1136\/ard.2009.112136_bib20","unstructured":"HUMIRA package insert. Abbott Laboratories, North Chicago, Illinois, USA, July 2007."},{"key":"10.1136\/ard.2009.112136_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.autrev.2005.07.006","article-title":"The CORRONA database","volume":"5","author":"Kremer","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard.2009.112136_bib22","unstructured":"Arava package insert. Sanofi Aventis, LLC, Bridgewater, New Jersey, USA, July 2007."},{"key":"10.1136\/ard.2009.112136_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.112136_bib24","unstructured":"US FDA. Guidelines for Industry-drug Induced Liver Injury: Premarketing Clinical Evaluation. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdf, (accessed 24 Oct 2007)."},{"key":"10.1136\/ard.2009.112136_bib25","series-title":"Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver","author":"Zimmerman","year":"1978"},{"key":"10.1136\/ard.2009.112136_bib26","unstructured":"FDA, Center for Drug Evaluation and Research, Arthritis Advisory Committee. Safety of TNF Inhibitors, 4 March 2003 (Transcript). http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/transcripts\/3930T1.htm, (accessed 18 September 2007)."},{"key":"10.1136\/ard.2009.112136_bib27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1172\/JCI110764","article-title":"Primate erythrocyte-immune complex-clearing mechanism","volume":"71","author":"Cornacoff","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2009.112136_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000024347","article-title":"IgG immune complex binding to and activation of liver cells. An in vitro study with IgG immune complexes, Kupffer cells, sinusoidal endothelial cells and hepatocytes","volume":"121","author":"Johansson","year":"2000","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1136\/ard.2009.112136_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrd2196","article-title":"Biologic therapies in rheumatology: lessons learned, future directions","volume":"6","author":"Strand","year":"2007","journal-title":"Nat Rev Drug Discov"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724193545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724193545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2009.112136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:10:48Z","timestamp":1737249048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724193545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0003496724193545"],"URL":"https:\/\/doi.org\/10.1136\/ard.2009.112136","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2009.112136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}